Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

计划入组 30 人 · 首次发布于 2023 年 3 月 14 日

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

计划入组 29 人 · 首次发布于 2023 年 4 月 7 日

Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)

计划入组 30 人 · 首次发布于 2021 年 8 月 16 日

PlyD1 pneumococcal vaccine (Netherlands Vaccine Institute)

NAD+ precursor(APeT Holding B.V.)

Apoptin gene therapy(Leadd B.V.)

Orchard Therapeutics (Netherlands) B.V.

Netherlands

Curium Netherlands B.V.

Netherlands

Corcept Therapeutics

United States

CHMP Backs 12 New Medicines, Including First Oral Daily Hidradenitis Suppurativa Option and Earlier-Line Tecvayli

Corcept's Relacorilant Shows Promise in Cushing's Syndrome Treatment

Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome